Prescription ·Strong evidence ·Reviewed May 2026
Candesartan is an angiotensin II receptor blocker (ARB) used to treat high blood pressure and chronic heart failure with reduced ejection fraction. It is administered as the prodrug candesartan cilexetil, which is rapidly converted to active candesartan during absorption from the gastrointestinal tract. By blocking the AT1 receptor it lowers blood pressure and reduces cardiovascular strain with a once-daily dosing profile.
The bottom line
Evidence rating strong. Most-documented uses: lowers blood pressure in essential hypertension, reduces cardiovascular morbidity and mortality in chronic heart failure with reduced ejection fraction, reduces heart failure hospitalizations. 4 sources indexed (2003–2018), with 6 interaction records on file.
Core mechanism
Candesartan selectively and competitively antagonizes the angiotensin II type 1 (AT1) receptor. By preventing angiotensin II from binding to AT1 receptors in vascular smooth muscle and the adrenal cortex, it inhibits angiotensin II mediated vasoconstriction and aldosterone secretion. The resulting vasodilation lowers peripheral vascular resistance and blood pressure, while reduced aldosterone decreases sodium and water retention. Because it acts downstream of angiotensin II rather than inhibiting its formation, it does not raise bradykinin levels, which accounts for the lower incidence of cough compared with ACE inhibitors. Reduced aldosterone activity decreases renal potassium excretion, which can raise serum potassium.1,2
Can be taken with or without food; food does not meaningfully affect bioavailability. Absolute bioavailability is low (about 15 percent) due to incomplete conversion of the prodrug, but absorption is consistent. May be taken at any consistent time of day.
Potassium supplements or potassium-containing salt substitutes can cause hyperkalemia with Candesartan.
Recommendation: Avoid unsupervised potassium supplementation; check potassium and kidney function after initiation, dose changes, or illness.
Magnesium Glycinate may add to the blood-pressure-lowering effect of Candesartan.
Recommendation: Monitor blood pressure and dizziness, especially during dose changes; stop the supplement and seek advice if syncope, falls, or symptomatic hypotension occurs.
L-Citrulline may add to the blood-pressure-lowering effect of Candesartan.
Recommendation: Monitor blood pressure and dizziness, especially during dose changes; stop the supplement and seek advice if syncope, falls, or symptomatic hypotension occurs.
Candesartan, an angiotensin II receptor blocker, raises serum potassium by reducing aldosterone-driven renal potassium excretion. Combining it with potassium supplements can produce additive hyperkalemia, which may cause dangerous cardiac arrhythmias, particularly in patients with chronic kidney disease, diabetes, heart failure, or older age.
Recommendation: Avoid routine potassium supplements while taking candesartan unless specifically prescribed and monitored by a clinician. Have serum potassium and renal function checked before starting and periodically thereafter. Report muscle weakness, palpitations, or irregular heartbeat promptly.
Garlic extract can produce a modest blood-pressure-lowering effect. Taken with candesartan, the antihypertensive effects may be additive, which could occasionally lead to dizziness, lightheadedness, or symptomatic low blood pressure, especially when standing.
Recommendation: If using garlic extract with candesartan, monitor blood pressure and rise slowly from sitting or lying positions. Report persistent dizziness or fainting to a clinician, who may adjust dosing.
Coenzyme Q10 has shown a mild blood-pressure-lowering effect in some trials. When combined with candesartan, the antihypertensive effect could be slightly additive, occasionally producing lightheadedness in sensitive individuals.
Recommendation: CoQ10 can usually be used alongside candesartan. Monitor blood pressure if starting CoQ10 and report symptoms of low blood pressure such as dizziness or fatigue so dosing can be reviewed.
Numbered references. Citations throughout the page link here.
Adding candesartan to ACE inhibitor therapy in heart failure with reduced ejection fraction significantly reduced cardiovascular death and hospital admission for heart failure.
Candesartan reduced cardiovascular mortality and heart failure hospitalization in ACE-inhibitor-intolerant patients with reduced ejection fraction.
Candesartan cilexetil is indicated for the treatment of hypertension and heart failure, providing sustained 24-hour blood pressure reduction with once-daily dosing.
Concomitant use of potassium supplements, potassium-sparing diuretics, or potassium-containing salt substitutes with candesartan may increase serum potassium and lead to hyperkalemia.
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
